Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that it has received new indication approval from the National Medical Products Administration (NMPA) for its drug Xpovio (selinexor). The drug is now approved for the treatment of adult patients with recurrent or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who have previously received at least two lines of systemic treatment.
Xpovio, originally discovered by Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a U.S.-based company, is recognized as the world’s first and only FDA-approved oral XPO1 inhibitor. In May 2018, Karyopharm granted Antengene the rights to the drug in Greater China, South Korea, and ASEAN countries. After being conditionally approved in China in November 2021, Xpovio has since received marketing approval in Taiwan, Hong Kong, Macau, South Korea, Singapore, and Australia.- Flcube.com
